NASDAQ:GALT

Galectin Therapeutics - GALT Stock Forecast, Price & News

$1.99

+0.04 (+2.05%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.91
▼
$1.99
50-Day Range: $1.10
▼
$2.40
52-Week Range: $1.02
▼
$2.57

Volume: 25,390 shs
Average Volume: 122,458 shs
Market Capitalization: $118.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Institutional Ownership

Galectin Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 452.8% Upside
$11.00 Price Target
Short Interest: Bearish
5.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$4,553 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.65) to ($0.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

722nd out of 999 stocks

Pharmaceutical Preparations Industry

356th out of 489 stocks

3.5

Analyst's Opinion

Consensus Rating
Galectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Galectin Therapeutics has a forecasted upside of 452.8% from its current price of $1.99.
Amount of Analyst Coverage
Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
5.00% of the float of Galectin Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Galectin Therapeutics has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Galectin Therapeutics has recently increased by 4.95%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Galectin Therapeutics does not currently pay a dividend.
Dividend Growth
Galectin Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GALT.

3.3

News and Social Media Coverage

News Sentiment
Galectin Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Galectin Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 2 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,553.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
44.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.64% of the stock of Galectin Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.65) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galectin Therapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galectin Therapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galectin Therapeutics has a P/B Ratio of 199.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GALT Stock News Headlines

March 20, 2023 | americanbankingnews.com

Galectin Therapeutics (NASDAQ:GALT) Receives New Coverage from Analysts at StockNews.com

March 16, 2023 | msn.com

Galectin gets safety board nod to continue trial of liver disease drug belapectin

March 29, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

March 16, 2023 | finance.yahoo.com

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

March 4, 2023 | benzinga.com

Galectin Therapeutics Stock (NASDAQ:GALT), Guidance and Forecast

March 2, 2023 | finance.yahoo.com

Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

January 30, 2023 | thestreet.com

Why Galectin Therapeutics (GALT) Stock Is Plummeting Today

January 24, 2023 | finance.yahoo.com

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

March 29, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

January 7, 2023 | thestreet.com

Galectin Therapeutics (GALT) Stock Drops on Drug Failure, Downgraded

January 5, 2023 | finance.yahoo.com

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

January 3, 2023 | seekingalpha.com

Galectin Therapeutics: In For A Long 2-Year Wait

December 13, 2022 | finance.yahoo.com

Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now

November 29, 2022 | finance.yahoo.com

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

November 14, 2022 | finance.yahoo.com

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

November 1, 2022 | finance.yahoo.com

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

October 14, 2022 | finance.yahoo.com

Galectin Therapeutics to Present in Upcoming Conferences

October 12, 2022 | marketwatch.com

Galectin Therapeutics Files FDA Application for Belapectin

October 12, 2022 | finance.yahoo.com

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

October 6, 2022 | finance.yahoo.com

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

September 8, 2022 | finance.yahoo.com

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

August 27, 2022 | finance.yahoo.com

Galectin Therapeutics Inc. (GALT)

August 15, 2022 | finance.yahoo.com

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

July 26, 2022 | finance.yahoo.com

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

July 11, 2022 | seekingalpha.com

Galectin: Ability To Potentially Target Unmet Medical Need

June 21, 2022 | finance.yahoo.com

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

May 17, 2022 | seekingalpha.com

Galectin Therapeutics GAAP EPS of -$0.17

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GALT Company Calendar

Last Earnings: 11/15/2021
Today: 3/28/2023
Next Earnings (Estimated): 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GALT
CUSIP: N/A
CIK: 1133416
Web: www.galectintherapeutics.com
Phone: (678) 620-3186
Fax: 770-864-1327
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +452.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,530,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -120.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.79
Quick Ratio: 1.79

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.01 per share
Price / Book: 199.00

Miscellaneous

Outstanding Shares: 59,610,000
Free Float: 32,962,000
Market Cap: $118.62 million
Optionable: Optionable
Beta: 1.42

Key Executives

Joel Lewis
President, Chief Executive Officer & Director

Jack W. Callicutt
Chief Financial Officer & Secretary

Pol F. Boudes
Chief Medical Officer

Ezra R. lowe
Executive Director-Clinical

Marla Mills-Wilson
Executive Director-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GALT Stock - Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GALT shares.
View GALT analyst ratings or view top-rated stocks.
What is Galectin Therapeutics' stock price forecast for 2023?: 1 analysts have issued 1 year price objectives for Galectin Therapeutics' stock. Their GALT share price forecasts range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 452.8% from the stock's current price.
View analysts price targets for GALT or view top-rated stocks among Wall Street analysts.
How have GALT shares performed in 2023?: Galectin Therapeutics' stock was trading at $1.13 on January 1st, 2023. Since then, GALT stock has increased by 76.1% and is now trading at $1.99.
View the best growth stocks for 2023 here.
When is Galectin Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our GALT earnings forecast.
How were Galectin Therapeutics' earnings last quarter?: Galectin Therapeutics Inc. (NASDAQ:GALT) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04.
What other stocks do shareholders of Galectin Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

What is Galectin Therapeutics' stock symbol?: Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."
Who are Galectin Therapeutics' major shareholders?: Galectin Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Advisor Group Holdings Inc. (2.13%), Geneos Wealth Management Inc. (0.73%), Atria Wealth Solutions Inc. (0.45%), Millennium Management LLC (0.44%), Cutter & CO Brokerage Inc. (0.22%) and Commonwealth Equity Services LLC (0.17%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Gilbert F Amelio, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani.
View institutional ownership trends.
How do I buy shares of Galectin Therapeutics?: Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Galectin Therapeutics' stock price today?: One share of GALT stock can currently be purchased for approximately $1.99.
How much money does Galectin Therapeutics make?: Galectin Therapeutics (NASDAQ:GALT) has a market capitalization of $118.62 million. The company earns $-30,530,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.
How can I contact Galectin Therapeutics?: Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The official website for the company is www.galectintherapeutics.com. The company can be reached via phone at (678) 620-3186, via email at ir@galectintherapeutics.com, or via fax at 770-864-1327.

This page (NASDAQ:GALT) was last updated on 3/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galectin Therapeutics - GALT Stock Forecast, Price & News

Galectin Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Galectin Therapeutics (NASDAQ:GALT) Stock

GALT Stock News Headlines

GALT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GALT Stock - Frequently Asked Questions

Overall MarketRank^™